Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-06-20
2010-11-09
Andres, Janet L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S124000
Reexamination Certificate
active
07829556
ABSTRACT:
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
REFERENCES:
patent: 3517007 (1970-06-01), Kim et al.
patent: 4018932 (1977-04-01), Spicer et al.
patent: 4939133 (1990-07-01), Connor et al.
patent: 6653309 (2003-11-01), Saunders et al.
patent: 7345178 (2008-03-01), Nunes et al.
patent: 2004/0176396 (2004-09-01), Biftu et al.
patent: 2004/0180905 (2004-09-01), Munchhof
patent: 2005/0245539 (2005-11-01), Mendla et al.
patent: 2007/0037809 (2007-02-01), Nunes et al.
patent: 2007/0037810 (2007-02-01), Nunes et al.
patent: 2007/0037827 (2007-02-01), Nunes et al.
patent: 2007/0037865 (2007-02-01), Nunes et al.
patent: 2009/0099170 (2009-04-01), Nunes et al.
patent: 2009/0163476 (2009-06-01), Milburn et al.
patent: 1 402 689 (1975-08-01), None
patent: 5076084 (1993-03-01), None
patent: 5289689 (1993-11-01), None
patent: 07291976 (1995-11-01), None
patent: WO 01/27119 (2001-04-01), None
patent: WO-03/007959 (2003-01-01), None
patent: WO-03/011219 (2003-02-01), None
patent: WO 03/028725 (2003-04-01), None
patent: WO 03/028728 (2003-04-01), None
patent: WO 03/042188 (2003-05-01), None
patent: WO 2004/080481 (2004-09-01), None
patent: WO 2005/058884 (2005-06-01), None
patent: WO 2005/069998 (2005-08-01), None
patent: WO-2006/053227 (2006-05-01), None
patent: WO-2006/094236 (2006-09-01), None
patent: WO 2007/019344 (2007-02-01), None
patent: WO-2008/106692 (2008-09-01), None
U.S. Appl. No. 11/885,557; Michael Milburn, et al; filed Sep. 4, 2007.
U.S. Appl. No. 12/070,350; Joseph Nunes, et al; filed Feb. 15, 2008.
Database Chemcats Chemical Abstracts Service, Columbus, OH, US; Jan. 18, 2005, XP002384121 ON's STK199474, STK199472, STK199473, STK180355, STK174405, STK196060, STK115373, STK164162, STK136073, STK164152, STK120473, STK052285 -& “Interchim Intermediates” Jan. 18, 2005, Interchim, Montlucon, France, XP002386059.
Jules et al., “Derivatives of 3-, 4-, and 5-Phenylsalicylamides”J. Am. Pharma. Assoc., 45(5):277-281 (1956).
Porcu et al., “The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension,”TRENDS in Pharmacological Sciences, 26(2):94-103 (2005).
Yogi et al., “Synthesis of Arylthio-Substituted 3,8-Diphenyl-1,2-diazacycloocta-2,4,6,8-tetraenes and Their Thermolysis”Bull. Chem. Soc. Jpn, 60(1):335-342 (1987).
Andreani et al.,“Thienylimidazo[2,1-b]thiazoles as Inhibitors of Mitochondrial NADH Dehydrogenase,” J. Med. Chem., 38:1090-97 (1995).
Andreani, et al., “6-(Hydroxyphenyl) Imidazo [2,1-b]Thiazoles as Potential Antiinflammatory Agents: Effects on Human Neutrophil Functions,” Collection of Czechoslovak Chemical Communications, 65:267-79 (2000).
Andreani, et al., “Synthesis and antitubercular activity of imidazol[2,1-b]thiazoles,” European J. Med. Chem., 36:743-746 (2001).
Andreani, et al., “Synthesis and antitumor activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones,” Anti-Cancer Drug Design, 16:167-174 (2001).
Barchechath et al., “Inhibitors of Apoptosis in Lymphocytes: Synthesis and Biological Evaluation of Compounds Related to Pifithrin-α,” J. Med. Chem., 48:6409-22 (2005).
Bienayme et al., “A New Heterocyclic Multicomponent Reaction For the Combinatorial Synthesis of Fused 3-Aminoimidazoles,” Angewandte Chemie International Edition, 37(16):2234-37 (1998).
Borra et al., “Mechanism of Human SIRT1 Activation by Resveratrol”, J. Biol. Chem., 280(17):17187-195 (2005).
Forti et al., “NADPH-generating system: influence on microsomal mono-oxygenase stability during incubation for the liver-microsomal assay with rat and mouse S9 fractions,” Mutation Research, 129:291-97 (1984).
Freymann et al., Efficient identification of inhibitors targeting the closed active site conformation of the HPRT from Trypansoma cruzi, Chemistry and Biology, 7:957-68 (2000).
Gemesi et al., “Application of LC-MS analysis to the characterisation of the in vitro and in vivo metabolite profiles of RGH-1756 in the rat,” Journal of Pharmaceutical and Biomedical Analysis, 24:877-85 (2001).
Hozien et al., “An Efficient Route for Synthesis of 5,6-Diphenylimidazo-[2,1-b]thiazoles as Antibacterial Agents,” J. Hetero. Chem., 37:943-49 (2000).
Ikeda et al., “Functional analysis of four naturally occurring variants of human constitutive androstane receptor,” Molecular Genetics and Metabolism, 86:314-19 (2005).
Jinno et al., “Identification of Novel Alternative Splice Variants of Human Constitutive Androstane Receptor and Characterization of Their Expression in the Liver,” Molecular Pharmacology, 65(3):496-02 (2004).
Kaeberlein et al., “Substrate-specific Activation of Sirtuins by Resveratrol”, J. Biol. Chem., 280(17):17038-45 (2005).
Laszlovszky et al., “Substituted phenoxyalkylpiperazines as dopamine D3 receptor ligands,” Pharmazie, 56(4):287-89 (2001).
Lewis et al., “Levamisole-Resistant Mutants of the Nematode Caenorhabditis Elegans Appear to Lack Pharmacological Acetylcholine Receptors,” Neuroscience, 5:967-89 (1980).
Pacholec et al., “SRT1720, SRT2183 and SRT1460 Do Not Activate Sirt1 with Native Substrates”, FASEB Summer Research Conferences; NAD Metabolism and Signaling, Jun. 21-26, 2009.
Terjeki et al., “An HPLC/UV method for the determination of RGH-1756 in dog and rat plasma,” Journal of Pharmaceutical and Biomedical Analysis, 24:913-20 (2001).
Yagodinets et al., “Convenient method for the synthesis of phosphorus-containing heterocyclic systems of imidazo[2,1-b]thiazoles, imidazo[2,1-a]pyridines and quinoxalines,” Zhurnal Obshchei Khimii, 54(12):2789-2790 (1984).
Yueh et al., “High Volume Bioassays to Assess CYP3A4-Mediated Drug Interactions: Induction and Inhibition in a Single Cell Line,” Drug Metabolism and Disposition, 33(1):38-48 (2005).
Pacholec et al., “SRT1720, SRT2183, SRT1460, and Resveratrol are not Direct Activators of SIRT1”, JBC Papers in Press, Manuscript M109.088682, Jan. 8, 2010.
Papers of the Week, “A Resveratrol Reversal”, DOI 10.1074/jbc.P109.088682, Mar. 10, 2010 (abstract).
Pacholec et al., “SRT1720, SRT2183, SRT1460, and Resveratrol are not Direct Activators of SIRT1”, J. of Bio. Chem., 285(11):8340-8351, Mar. 12, 2010.
Bemis Jean
Disch Jeremy S.
Jirousek Michael
Lunsmann Walter Joseph
Ng Pui Yee
Andres Janet L
Robinson Binta M
Ropes & Gray LLP
Sirtris Pharmaceuticals, Inc.
LandOfFree
Sirtuin modulating compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sirtuin modulating compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sirtuin modulating compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4221085